Start with the forum and the stakes. The U.S. International Trade Commission can issue exclusion orders that block infringing products at the border — a remedy district courts rarely match in speed or bite. For a consumer-device maker, an ITC posture is uniquely dangerous because it threatens the ability to import the product at all, not just to pay damages later. The Masimo/Apple pulse-oximetry dispute is the template the whole industry now reads from: an asserted sensor patent, an ITC action, and ultimately a blood-oxygen feature disabled on shipping watches to keep them importable.
Why sensors specifically? Because the blast radius of a ban depends on how cleanly the asserted patent maps to a removable feature. A patent that reads on a discrete sensor — pulse oximetry, ECG, blood-pressure estimation — lets a respondent surgically disable that one function and keep selling the device. That makes the feature both the target and the relief: the ban's blast radius is exactly one sensor wide. A patent that read on the whole phone would be harder to enforce against; a patent that reads on one sensor is a precision instrument.
Now connect that to live assets. Samsung holds granted — issued, assertable — claims on cuffless blood-pressure estimation: US12557995B2 (February 24, 2026) and US12543963B2 (February 10, 2026), both in the blood-pressure-measurement class A61B 5/02116. These are the kind of claims that map to a discrete wrist feature. Whether or not they are ever asserted, they are structurally the right shape for the next sensor fight — narrow, granted, and pointed at a removable function.
The procedural discipline this beat demands: holding a patent is not the same as asserting it, and being sued is not the same as infringing. I am describing the shape of the risk, not predicting a case. An ITC complaint requires a domestic-industry showing and survives validity challenges only sometimes; many sensor patents would not clear that bar. The point is that the category — wearable health sensing — combines coveted features, dense overlapping portfolios, and feature-level claims, which is the exact recipe that produced Masimo/Apple.
For a strategist tracking exposure: the product line at risk is the high-margin flagship watch, and the relief that bites is feature disablement. When you see granted, feature-level health-sensor claims accumulating — as they are at Samsung, and across the wrist-sensor field — read them as loaded assets in a category where the ITC remedy has already proven it can reach into a shipping product and switch a sensor off.